Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 19/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19451849 | 1.00 | STING1 (0.81) | STING1CYP3A4ENPP1 | |
| SCHEMBL19451788 | 0.94 | STING1 (0.87) | STING1CYP3A4ENPP1 | |
| SCHEMBL19436571 | 0.93 | STING1 (0.84) | STING1CYP3A4ENPP1 | |
| SCHEMBL19436569 | 0.93 | STING1 (0.84) | STING1CYP3A4ENPP1 | |
| Hydrochloric Acid SCHEMBL21616403 | 0.92 | STING1 (0.83) | STING1CYP3A4ENPP1 | |
| Hydrochloric Acid SCHEMBL29686248 | 0.92 | STING1 (0.83) | STING1CYP3A4ENPP1 | |
| SCHEMBL24467556 | 0.91 | STING1 (0.82) | STING1CYP3A4ENPP1 | |
| SCHEMBL19451525 | 0.91 | STING1 (0.85) | STING1CYP3A4ENPP1 | |
| SCHEMBL23077571 | 0.91 | STING1 (0.81) | STING1CYP3A4ENPP1 | |
| SCHEMBL23077570 | 0.91 | STING1 (0.81) | STING1CYP3A4ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200330556-A1 | Methods for Administering STING Agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | claimed |
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | claimed |
| US-12178851-B2 | Methods for administering STING agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-12-31 | — | — | US | disclosed |
| EP-4032885-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2022-07-27 | — | — | EP | disclosed |
| EP-3440076-B1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-06-01 | — | — | EP | disclosed |
| US-20210238172-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20200330556-A1 | Methods for Administering STING Agonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| EP-3692033-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-08-12 | — | — | EP | disclosed |
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | disclosed |
| WO-2019069269-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) USEFUL IN TREATING HIV | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330556-A1 | Methods for Administering STING Agonists | STING1, CGAS, TLR9 | STING1 1/4885CYP3A4 4770/4885ENPP1 898/4885 |
| US-20210238172-A1 | HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS AND METHODS OF USING THE SAME | AADAC, TAF15, HDAC10 | STING1 748/4885CYP3A4 3022/4885ENPP1 1342/4885 |
| US-12178851-B2 | Methods for administering STING agonists | STING1, CGAS, TLR9 | STING1 1/4885CYP3A4 4770/4885ENPP1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.